TE 8214
Alternative Names: TE-8214Latest Information Update: 23 Apr 2024
At a glance
- Originator Immunwork
- Class Antidiarrhoeals; Antineoplastics; Cyclic peptides; Drug conjugates; Fatty acids; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Insulin-like growth factor I inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Neuroendocrine tumours
Most Recent Events
- 19 Apr 2024 Immunwork plans a phase I trial for Acromegaly (In volunteers)in Australia (SC) in May 2024 (NCT06372652)
- 05 Jan 2023 TE 8214 is available for licensing as of 05 Jan 2023. https://www.immunwork.com/eforms.php?lang=en&tb=1
- 05 Jan 2023 Preclinical trials in Neuroendocrine tumours in Taiwan (SC) before January 2023 (Immunwork pipeline, January 2023)